Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0699790 (colon cancer)
 28,837 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

CEA levels in serum are not reliable markers of tumors. In this paper a method for determination of this antigen for tissue sections is given. Histology, immunohistology and serum levels of CEA were compared. Tissue sections were obtained by surgical and endoscopic techniques. In several cases there was a discrepancy between serological and morphological results. Based on recent investigations elevated CEA levels might be only useful in reflecting a relapse of carcinoma of the colon. Immunohistological determinations were done by IFT and PAP-method. The results of both assay systems were comparable. CEA could be also detected in benign neoplasiogenic tissue, i.e. in tubular type of adenomatose polyps and in ulcerative colitis. Both diseases are known to become malignant at an high degree. By contrast no CEA could be detected in hyperplasiogenic polyps. Detection of CEA in malignant tissue might be useful for final classification of tumors. Occurrence of CEA in non malignant tissue should give rise to control in short regular intervals. Prospective studies might show the reliability of the CEA-bearing cells of non malignant tissue.
 ...
PMID:[Immunohistologic determination of a tumor marker (CEA) in diseases of the gastrointestinal tract]. 637 75

The response rate of metastatic colorectal carcinoma confined to the liver to HAI of FUDR alone is at the range of 50% and to mitomycin C by hepatic arterial infusion (HAI) at the range of 35%. Mitomycin C was added to FUDR by continuous infusion and given by HAI to 12 patients with colorectal cancer confined to the liver. Catheters were placed subselectively in the hepatic artery, and infusion continued for five to six days when the catheter was removed. Cycles were repeated every 30 days. Chemotherapy consisted of mitomycin C 15 mg/m2 administered on day 1 followed by FUDR 100 mg/m2 by continuous infusion daily for five days. Response to treatment was evaluated by serial determinations of plasma CEA and by imaging techniques consisting of a computerized tomography, sonography, and radionuclide scanning of liver as well as by angiography. In 2 patients, complete remission was achieved; in 4 patients a 75% and in another 4 patients a 50% decrease in liver metastasis was observed, while 2 patients had stable disease. Thus, a response rate of 83% with a median duration of six to seven months was achieved. The median survival of the these patients was 16 months. Eight of the 12 patients have failed previous, i.v. 5-FU containing regimens. Complications related to 45 treatment cycles were the following: catheter displacement in 11.1%, an intimal tear, usually in the hepatic artery in 4.4%, gastric ulcerations in 5.4%, and septicemia in 2.7% of the cycles. In addition, aneurysmal dilation of the hepatic artery occurred in 4 patients (8.8% of the treatment cycles), all of whom continued treatment. Chemotherapy-related complications included primarily thrombocytopenia and stomatitis. Mitomycin C + FUDR by hepatic arterial infusion is an effective treatment for colorectal carcinoma metastatic to the liver. The high response rate justifies the adjuvant treatment of Dukes class C colon cancer patients with this treatment.
 ...
PMID:Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): an effective treatment for metastatic colorectal carcinoma in the liver. 644 76

We have reviewed the CT scans of 30 patients who were evaluated for either primary or recurrent carcinoma of the colon and rectum in the pelvis. The results of our experience have shown that pelvic CT scans can provide accurate information regarding the extramural extension of carcinoma of the rectosigmoid undetected by other means. CT scans can detect significant ureteral pathology as accurately as can IVP and have essentially replaced the IVP in the preoperative evaluation of carcinoma of the rectum. Inflammation of the perirectal musculature, either by the effect of the local tumor or secondary to preoperative radiation, can make it difficult to determine if these structures are invaded by tumor. Tumor involvement, however, can be proved using CT localization and percutaneous fine needle aspiration biopsy techniques. During radiation therapy and chemotherapy, CT scans may also assist in treatment planning and may be the most reliable way of observing the objective response of the recurrent tumor in the pelvis. Finally, in the patient in whom the recurrent tumor does not produce abnormally high levels of CEA, the CT scan may be the only method by which the early and treatable recurrence may be detected. It is, therefore, appropriate to recommend that pelvic CT scan be a routine test for every patient who has had abdominoperineal resection or low anterior resection for carcinoma of the rectum and rectosigmoid.
 ...
PMID:The use of computerized tomography scan in the staging and follow-up study of carcinoma of the rectum. 648 90

The Dukes' and TNM systems for staging carcinoma of the colon and rectum are still the best pathologic classifications, but they do not apply to all patients and do not distinguish between patients who will die and patients who will be cured by the same therapeutic procedure. A new approach to this problem should be to establish a biochemical automatic classification, complementary to the morphologic one, which allow us to classify every patient before and after the first and subsequent treatments. By using several nonspecific tumor markers, such as CEA, AAT, AF, AAG, GGT and transferrine, a discriminant analysis was executed among the groups of patients with LD, RD and DD. Our initial results with only 12.8 per cent of incorrect classifications, that is patients classified in a less advanced group, suggest that this system may be quite useful in order to select those patients with carcinoma of the rectum who should benefit from preoperative radiotherapy as well as those who should receive adjuvant therapy after the first treatment. On the other hand, for patients classified in a more advanced group than the pathologic grading, we may well be able to identify those patients with occult disease for which the frequency of revisions should be shorter.
 ...
PMID:Automatic preoperative classification of carcinoma of the colon and rectum. 671 Mar 17

Cells of colonic carcinoma line HT-29, cultured over more than 170 generations and extensively used in immunological studies of patients with colorectal tumours, still express several immunologically valuable characteristics presumably present since its inception. The cell line can induce a poorly differentiated adenocarcinoma in the nude mouse, it has human antigenic characteristics, it expresses blood group A antigen, and produces a colon-specific mucin and CEA, though not colon cancer-specific mucin (CCM). It remains useful as a target for in vitro testing of anti-tumour immunoreactivity in colorectal cancer patients.
 ...
PMID:Persistence of organ- and iso-antigens in vitro in a long-term culture cell line of colonic carcinoma. 676 88

5-Fluorouracil (5-Fu) was administered by a constant venous infusion schedule at a dose of 300 mg/m2/d for 30-180 days. The dose schedule was associated with minimal toxicity in 32 patients with gastrointestinal cancer treated by employing a portable infusion pump for ambulatory drug delivery. Cumulative dose of 5-Fu was extended to three to four times that achieved by intermittent bolus therapy or short-term 5-day infusion therapy. Objective tumor regression was observed in six of 22 patients with measurable disease; 10 patients had stable disease, five of whom had a decrease in CEA levels. The responses according to tumor type were as follows: 1/1 gastric cancer; 1/2 hepatoma; and 4/18 colon cancer. The superiority of this new treatment schedule for 5-Fu will need to be established by prospective randomized clinical trials.
 ...
PMID:Protracted ambulatory venous infusion of 5-fluorouracil. 683 1

Fifty-two patients with resectable carcinoma of the colon and rectum have been monitored by three monthly serial estimations of three APRP (serum protein hexose, transferrin and ceruloplasmin) together with CEA. In 36 patients, subsequent clinical evidence of a recurrence of the disease developed during the study period. Monitoring with APRP can detect a recurrence of the disease at the subclinical stage in the majority of patients and appears to be complimentary to monitoring with CEA. However, due to the low incidence of surgical removal of recurrent carcinoma, this does not give real benefit for patients.
 ...
PMID:Monitoring of patients with carcinoma of the large intestine by use of acute phase proteins and carcinoembryonic antigen. 685 57

The occurrence of CEA was extensively adsorbed to eliminate cross-reactions with CEA-related antigens. After the first trimester of pregnancy CEA was found throughout the gastrointestinal tract by both techniques, whereas the other fetal tissues and fetal serum did not contain detectable amounts of CEA. The CEA-level of all 69 sera of pregnant women was below 2.5 ng/ml. The excretory nature of CEA was suggested by the localization of CEA in the luminal border of the alimentary tract and by the finding that the CEA concentration in the content of fetal gastrointestinal canal was higher than in the surrounding tissue. Gel filtration on Sepharose 4B showed that molecular weight of CEA immunoreactive material of the fetal gut was similar to that of CEA purified from colon cancer, but a minor component with a higher molecular weight was eluted in the void volume. When tested in radioimmunoassay, the CEA immunoreactive material in both peaks gave an inhibition curve parallel to that of purified CEA.
 ...
PMID:Carcinoembryonic antigen in fetal tissues and in material serum. 699 Jun 84

Many studies reported the pretreatment with methotrexate followed by 5-FU resulted in the greatest tumor cell killing. Our preliminary laboratory studies confirmed the possibility of drug synergism in the L1210 cell line, but not in human bone marrow cells. Thirteen patients with metastatic adenocarcinoma of the breast and seven patients with metastatic adenocarcinoma of the colon were treated with an innovative approach in which methotrexate preceded 5-FU administration in an attempt to cause drug synergism and prevent drug antagonism. All patients with breast cancer and two patients with colon cancer had been extensively pretreated with multiple drugs. Of the cancer patients so treated, three (23%) with breast cancer and two (28%) with colon cancer demonstrated objective tumor response. In addition to these patients, six (46%) with breast cancer and three (43%) with colon cancer demonstrated subjective improvement as manifested by total pain relief and reduction in CEA titer. The preliminary results reported in this study suggest that sequential utilization of intermediate doses of methotrexate, followed by high doses of 5-FU, is an effective combination chemotherapy for patients with breast and colon malignancies.
 ...
PMID:Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon. 744 20

Two human ovarian (OV-MZ-10, OV-MZ-15) and two colon cancer cell lines (CO-MZ-5, CO-MZ-6) were newly established in permanent cell culture. These cell lines have been maintained in vitro for 5-6 years, the passage number varying from 25 to 228. They were established from ascites or solid tumours at the time of primary surgery. By clinical and histopathological judgement alone all four cell lines would have been interpreted as ovarian cancer cell lines. Morphological criteria or the expression of the tumour-associated antigens CA-125 and CEA allowed no differential diagnosis. Only the analysis of the expression of different cytokeratins and vimentin enabled us to verify the different origin of the cell lines. Ovarian cancer cell lines, in contrast to the colon cancer cell lines, are positive for the expression of cytokeratin (CK) 7 and for vimentin. CK 20 proved to be the marker with the best discrimination. CK 20 was found exclusively in the colon carcinoma cell lines, but not in the ovarian carcinoma cell lines. The evaluation of cytokeratin expression is a helpful diagnostic modality in differentiating between adenocarcinoma cell lines derived from ovarian and colon tumours.
 ...
PMID:Establishment of new ovarian and colon carcinoma cell lines: differentiation is only possible by cytokeratin analysis. 751 Jan 15


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>